LONDON, March 16 (Reuters) – A first-in-class melanoma drug from Amgen based on a tumour-killing virus has been deemed not worth using on Britain’s state health service by the country’s…
The post UK cost agency rejects Amgen’s virus-based cancer drug appeared first on NASDAQ.